Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 7/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | TACR3 | P29371 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31444405 | 0.96 | HSP90AA1 (0.43) | SCN9AFFAR2HSP90AA1HSP90AB1NTRK1 | |
| SCHEMBL31444410 | 0.96 | HSP90AA1 (0.43) | SCN9AFFAR2HSP90AA1HSP90AB1NTRK1 | |
| SCHEMBL31444386 | 0.88 | SCN9A (0.42) | SCN9AFFAR2HSP90AA1HSP90AB1NTRK1 | |
| SCHEMBL31443502 | 0.79 | SCN9A (0.44) | SCN9ANTRK1JAK2 | |
| SCHEMBL31444371 | 0.78 | NTRK1 (0.38) | FFAR2HSP90AA1HSP90AB1NTRK1 | |
| SCHEMBL31444375 | 0.76 | HSP90AA1 (0.42) | FFAR2HSP90AA1HSP90AB1NTRK1 | |
| SCHEMBL31444295 | 0.76 | PDE5A (0.46) | FFAR2HSP90AA1HSP90AB1 | |
| SCHEMBL31444378 | 0.75 | RIPK1 (0.41) | FFAR2HSP90AA1HSP90AB1NTRK1 | |
| SCHEMBL24313136 | 0.73 | PRCP (0.41) | — | |
| SCHEMBL31444272 | 0.71 | HSP90AA1 (0.43) | FFAR2HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |